Randomized trials comparing Telmisartan vs. Valsartan and Losartan 24-hour ambulatory blood pressure control, GLP-1 heart failure outcomes, UKPDS 34 cardiovascular mortality reductions, and statin + ezetimibe ApoB targets. Explore 714 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Our results indicate that more intensive BP control is associated with a reduction in heart and blood vessel morbidity and mortality in patients with hypertensive PAD.
The addition of atorvastatin to metformin improved HbA1c and LDL-C levels to a significant extent compared to metformin or atorvastatin alone in diabetes and high cholesterol patients.
Protein levels of VEGF-A, angiopoietin-2 and rs6770663 in KCNAB1 are independent risk factors and, when combined, may improve prediction of bevacizumab-induced high blood pressure.
Our findings suggest that ISSD is a more severe phenotype of the disorder associated with a higher risk of high blood pressure.
In patients with T2DM and CVD, metformin and SGLT2 inhibitors were associated with substantially lower all-cause mortality rates and slightly longer life expectancies than in patients without.
These results may indicate the superiority of atorvastatin over rosuvastatin in inhibiting adverse changes in bone turnover in postmenopausal women.
No clinically meaningful differences were found across subgroups that were ADA-NEG, ADA-POS/NAb-NEG, and ADA-POS/NAb-POS, in terms of PKs (sotatercept trough concentration over time, mean postdose trough concentration at the...
No serious side effects occurred, and no statistically significant differences in the incidence of overall AEs and adverse drug reactions occurred among the three groups..
Based on our results, synbiotic had beneficial effects on some pregnancy outcomes.
This meta-analysis showed that 5 mg rosuvastatin/10 mg ezetimibe had largely comparable lipid-modifying efficacy and tolerability as 20 mg rosuvastatin.
This early health technology assessment model used inclusion criteria from clinical trials.
The most common AEs in the fostamatinib group were diarrhea (26.7%), high blood pressure (24.4%), and fatigue (15.6%).
Group A's LDL-c reduction effect and target achievement proportion (Rosuvastatin 10mg + Ezetimibe 10 mg) were significantly higher than Group B's (Rosuvastatin 20 mg).
This study offers reassurance that TRT does not increase mortality risk or worsen heart and blood vessel outcomes in hypogonadal men.
Among ASCVD patients, there was no heterogeneity in the effect of moderate-intensity statin plus ezetimibe combination therapy in the higher and lower baseline LDL-C levels for the 3-year composite of heart and blood vessel...
In high ASCVD risk patients with T2DM, the combination of moderate-intensity rosuvastatin and ezetimibe was not only non-inferior but also superior to improving high cholesterol with additional benefits compared to...
EPA, especially icosapent ethyl, plus statins had a beneficial effect on reducing the risk of MACEs and mortality in post-PCI patients.
Pravastatin lowers blood total cholesterol, LDL cholesterol and triglyceride in a dose-dependent linear fashion.
46.8%, p = .042) Our study showed standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg is efficacious and safe in treatment of primary high blood pressure.
In the asciminib cohort, adverse reactions of at least grade 3 with an incidence ≥ 5% were thrombocytopenia, neutropenia, increased pancreatic enzymes, high blood pressure, and anemia.
Surgical morbidity and mortality was comparable, whereas more non-surgical grade ≥ 3 side effects were observed with the combination, especially anorexia (A:1% B:11%), high blood pressure (A:4% B:13%) and infections (A:19% B:33%).
In patients with known heart and blood vessel disease (CVD), ezetimibe with a statin decreases major adverse heart and blood vessel events (MACE) but has no effect on all-cause and heart and blood vessel mortality, compared to...
Fixed dose combination of ezetimibe/rosuvastatin (10 mg/10 mg) achieved bioequivalence with reference to commercial tablets.
However, early plasma levels of succinate and other metabolites obtained from peripheral blood does not correlate with the degree of irreversible injury or area at risk in STEMI patients, and cannot be considered as predictors...
Conclusion: This review further confirms that high-intensity statins reduce LDL by ≥50%, favoring rosuvastatin over atorvastatin.
OLZ/SAM treatment was associated with lower risk of worsening cardiometabolic risk factors related to obesity, high blood pressure, and metabolic syndrome relative to olanzapine.
These results confirm that esaxerenone has a direct UACR-lowering effect independent of BP lowering and that its magnitude is much larger than that of the BP-dependent effect.
The administration of once-weekly Semaglutide exhibited a substantial reduction in HbA1c, average systolic blood pressure (SBP), mean diastolic blood pressure (DBP), body weight, waist circumference, body mass index (BMI), and...
Getting both at the same time of rosuvastatin and ezetimibe showed no clinically significant how the body absorbs the medicine interactions in a healthy Chinese population.
The reduction of DBP is greater treated with telmisartan than perindopril in patients with essential high blood pressure (Tab.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
